Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06647238 · ClinicalTrials.gov registry record · NA

Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention

A NA study of Coronary Artery Disease and Hyperlipidemia, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT06647238 is a NA study of Coronary Artery Disease and Hyperlipidemia that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 80 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06647238, a NA study of Coronary Artery Disease and Hyperlipidemia, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.

Interventions

  • OTHER Pharmacist Intervention in lipid therapy

Study Locations (1)

North Carolina

  • Atrium Health Cabarrus - Concord

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-11-05
Est. Completion 2025-05-27
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT06647238

The ClinicalTrials.gov registry entry for NCT06647238 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Pharmacist Intervention in lipid therapy is the first listed.

NCT06647238 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06647238 about?

NCT06647238 is a clinical study titled "Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention". The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.

What is the current status of trial NCT06647238?

This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2024-11-05. Estimated completion is 2025-05-27.

What conditions does trial NCT06647238 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Hyperlipidemia.

What interventions are being tested in trial NCT06647238?

The interventions under investigation include: Pharmacist Intervention in lipid therapy (OTHER).

Who is sponsoring clinical trial NCT06647238?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06647238 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.